Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 699-704

  García Gascó, Pilar ^a   Maida, Ivana ^a   Blanco, Francisco ^a   Barreiro, Pablo ^a   Martín Carbonero, Luz ^a   Vispo, Eugenia ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Blips; Drug resistance; Viral load; Virological failure

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FREQUENCY ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 40149103159     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm516     Document Type: Article

References (32)

1. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. The Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
2. Palella F, Defaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
3. Chene G, Sterne J, May M et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003; 362: 679-86.
4. Greub G, Cozzi-Lepri A, Ledergerber B et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16: 1967-9.
5. Havlir D, Bassett R, Levitan D et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286: 171-9.
6. Mocroft A, Ruiz L, Reiss P et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741-51.
7. Phillips A, Miller V, Sabin C et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15: 2379-84.
8. Sklar P, Ward D, Baker R et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002; 16: 2035-41.
9. Nettles R, Kieffer T, Kwon P et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-29.
10. Lee P, Kieffer T, Siliciano R et al. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57 803-5.
11. Stosor V, Palella F, Berzins B et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 2005; 41: 1671-4.
12. Karlsson A, Younger S, Martin J et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18: 981-9.
13. Mira J, Macias J, Nogales C et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002; 7: 251-6.
14. Martinez V, Marcelin AG, Morini J et al. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS 2005; 19: 1065-9.
15. Cohen-Stuart J, Wensing A, Kovacs C et al. Transient relapses ('blips') of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28: 105-13.
16. Macias J, Palomares J, Mira J et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 2005; 51: 195-200.
17. Phillips A, Staszewski S, Lampe F et al. HIV rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186 1086-91.
18. Phillips A, Ledergerber B, Horban A et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004; 18: 1795-804.
19. Smith C, Phillips A, Hill T et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study. J Infect Dis 2005; 192: 1387-97.
20. Sungkanuparph S, Overton E, Seyfried W et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41: 1326-32.
21. Abgrall S, Duval X, Joly V et al. Clinical and immunologic outcome in patients with HIV infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis 2003; 37: 1517-26.
22. Di M, Markowitz M, Louie M et al. Dynamics of intermittent viremia during highly active antiretroviral, therapy in patients who initiate therapy, during chronic versus acute and early HIV type 1 infection. J Virol 2004; 78: 10566-73.
23. Easterbrook P, Ives N, Waters A et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 2002; 16: 1521-7.
24. Moore A, Youle M, Lipman M et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16: 615-8.
25. Sungkanuparph S, Groger R, Overton E et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7: 437-41.
26. Dornadula G, Zhang H, van Uitert B et al. Residual HIV-1 RNA in blood and plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627-32.
27. Chun T, Nickle D, Justement J et al. HIV-infected individuals receiving effective-antiretroviral therapy for extended periods of time continuously replenish their viral reservoir. J. Clin Invest 2005; 115: 3250-5.
28. Jones L, Perelson A. Transient viremia, plasma vital load, and reservoir replenishment in HIV-infected patient on antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 45: 83-93.
29. Miller L, Golin C, Liu H et al. No evidence of an association between transient HIV viremia ('blips') and lower adherence to the antiretroviral medication regimen. J Infect Dis 2004; 189: 1487-96.
30. de la Rosa R, Ruiz-Mateos E, Rubio A et al. Long-term virological outcome and resistance mutations at virological bound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004; 53: 95-101.
31. Paterson D, Swindells S, Mohr J et al. Adherence to protease inhibitor. therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
32. Gulick R, Ribaudo H, Shikuma C et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-61.